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Abstract 
Treatment intensification to maximize disease control and reduced-intensity approaches to 
minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. 
The influence of these interventions on the risk of secondary malignant neoplasms, progression-
free survival and overall survival is reported in the present meta-analysis based on individual 
patient data from 9498 patients treated within 16 randomized controlled trials for newly diagnosed 
Hodgkin lymphoma between 1984 and 2007. Secondary malignant neoplasms were meta-
analyzed using Peto’s method as time-to-event outcomes. For progression-free and overall 
survival, hazard ratios derived from each trial using Cox regression were combined by inverse-
variance weighting. Five study questions (combined-modality treatment vs chemotherapy alone; 
more extended vs involved-field radiotherapy; radiation at higher doses vs radiation at 20 Gy; 
more vs fewer cycles of the same chemotherapy protocol; standard-dose chemotherapy vs 
intensified chemotherapy) were investigated. After a median follow-up of 7.4 years, dose-
intensified chemotherapy resulted in better progression-free survival (p=0.007) rates as compared 
with standard-dose chemotherapy, but was associated with an increased risk of therapy-related 
acute myeloid leukemia/myelodysplastic syndromes (p=0.0028). No progression-free or overall 
survival differences were observed between combined-modality and chemotherapy alone, but 
more secondary malignancies were seen after combined-modality (p=0.010). For the remaining 
three study questions, outcomes and secondary malignancy rates did not differ significantly 
between treatment strategies. The results of this meta-analysis help to weigh up efficacy and 
secondary malignancy risk for the choice of first-line treatment of Hodgkin lymphoma patients. 
However, final conclusions regarding secondary solid tumors require longer follow-up. 
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Introduction 
Hodgkin lymphoma (HL) is a lymphoid malignancy with an incidence of 3-4/100.000/year. Young 
adults are most often affected.1 At present, about 80% of patients achieve long-term remission 
after treatment with multi-agent chemotherapy optionally followed by radiotherapy (RT).2 Given the 
mostly young age at diagnosis and the excellent long-term prognosis, therapy-related late effects 
including secondary malignant neoplasms (SMN), cardiovascular disease and infertility have 
become increasingly important.3-6 Several recent clinical trials evaluated the possibility of reducing 
toxicity by limiting chemotherapy and RT without compromising efficacy.2 Conversely, some 
studies for patients with newly diagnosed advanced HL investigated intensified chemotherapy 
protocols to improve the clinical outcome of high-risk patients.2  
SMN are divided into secondary hematological malignancies including therapy-related acute 
myeloid leukemia/myelodysplastic syndromes (t-AML/MDS) and secondary non-Hodgkin 
lymphomas (NHL) and the heterogeneous group of secondary solid tumors. An association 
between the use of alkylating agents and topoisomerase-II-inhibitors and the development of t-
AML/MDS has been demonstrated.7-9 Both drug classes are included in first-line chemotherapy 
protocols such as ABVD, escalated BEACOPP and Stanford V.10-12 For secondary NHL, such 
associations have not been identified.13 The time interval between HL treatment and the 
occurrence of secondary hematological malignancies is usually short, ranging between four and 
ten years in most cases.9, 13 In contrast, the risk of secondary solid tumors remains significantly 
increased for up to 25 years and more.3, 4 
In the present meta-analysis using individual patient data (IPD), SMN, progression-free survival 
(PFS) and overall survival (OS) of patients treated in randomized clinical trials comparing different 
treatment approaches (combined-modality treatment (CMT) vs chemotherapy alone; more 
extended radiotherapy (RT) vs involved-field RT (IF-RT); RT at higher doses vs RT at 20 Gy; more 
vs fewer cycles of the same chemotherapy protocol; standard-dose chemotherapy vs intensified 
chemotherapy) were investigated. Acceptable chemotherapy regimens were ABVD or similar (e.g., 
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MOPP/ABV) or (for the last study question above) any dose-intensified chemotherapy randomly 
compared with a standard dose ABVD-like regimen.  
Methods 
Searches for randomized clinical trials including patients with newly diagnosed HL that compared 
treatment approaches according to the mentioned study questions and published from 1984 
onwards were performed in March 2010 using the electronic literature databases Medline and 
Cochrane Central. Reference lists of all relevant retrieved publications and previous meta-
analyses were searched. All identified articles were screened independently by two authors. Trials 
had to have enrolled at least 50 patients per treatment group and to have finished recruitment 
before or during 2007, to avoid trials with inadequate follow-up. Searches were repeated in April 
2015. 
IPD were requested from the investigators of the eligible trials, including birth date, sex, HL 
diagnosis date, stage at diagnosis, presence of B symptoms, randomization date, allocated 
treatment, remission status after first-line treatment, relapse date, date and type of SMN, death 
date and last follow-up date concerning clinical outcome and vital status.  
Statistical methods 
For quality control, each trial included in the meta-analysis was initially analyzed separately, 
comparing the treatment arms with respect to recruitment times, patient characteristics, complete 
remission rates, follow-up duration, PFS, OS and time to SMN. Results were compared with 
previous trial publications and inconsistencies queried. Risk of bias was assessed for each trial 
according to the Cochrane recommendations.14 To assess completeness of follow-up, the median 
observation time was calculated using the Kaplan-Meier method with reverse censoring at death. 
The distribution of last information dates was quantified using the interquartile range of the dates 
of last information (IQR-DLI). This range includes the central 50% of last information dates and 
thus represents the extent to which patients in a given study are lost to follow-up over a broad time 
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interval. Large IQR-DLI values (absolute or relative to median follow-up) suggest poorer follow-up 
quality.  
Randomized comparisons for each study question were combined across the appropriate trials to 
obtain a pooled Peto´s odds ratio (OR) for SMN rates, with 95% confidence intervals (CI).15, 16 
Three types of SMN, i.e. t-AML/MDS, secondary NHL and secondary solid tumors were also 
analyzed separately.  
Subgroup analyses were performed to investigate whether the SMN rates depended upon the 
stage according to Ann Arbor classification (early stages I and II vs advanced stages III and IV), 
age (≤50 years vs >50 years) and gender. Treatment subgroups were defined for the intensified 
chemotherapy question only (escalated BEACOPP vs Stanford V vs EBV/CAD-based vs ChlVPP-
based). Results were displayed chronologically by recruitment period in order to reveal time period 
effects. 
Sensitivity analyses were conducted excluding SMN that had occurred after HL recurrence: follow-
up times were censored at HL recurrence. Further sensitivity analyses were performed as follows: 
firstly, SMN data were analyzed using a one-step Cox proportional hazards regression, stratified 
by trial. Secondly, analyses were repeated with the exclusion of the less complete follow-up 
periods in each trial, censoring at the date at which 75% of surviving patients in the particular trial 
were still being followed. Thirdly, overall SMN and separate secondary solid tumor analyses were 
repeated excluding non-melanoma skin cancers (NMSC). Finally, the cumulative incidence 
method, which considers non-SMN death as a competing risk, was employed.17, 18 
All analyses were performed in SAS (version 9.3) and RevMan (version 5.2). 
 
Results 
Results of the search 
A total of 3515 references (excluding duplicates) published after 1984 were identified in 2010 and 
reviewed for eligibility. The majority did not meet the predefined criteria and were excluded for the 
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following reasons: 1419 references did not concern HL patients, 1162 did not report a clinical trial, 
161 reported on patients in the second-line setting, 98 reported non-randomized trials, 97 were 
review articles and 53 were duplicates. Hence, 578 references fulfilled the predefined general 
eligibility criteria and were reassessed concerning the exact treatment comparison. A total of 21 
randomized clinical trials for the first-line treatment of HL including at least 50 patients per study 
arm and comparing treatment modalities matching with at least one of the five study questions 
were identified. Data were received for 16 trials conducted between 1984 and 2007 (Figure 1).19-33 
No data were received for four studies.34-37 One additional trial first published in 2013 was only 
found in the 2015 search, so IPD were not sought.38 One trial was split for analysis since the 
participating centers could choose between two alternative intensified chemotherapy regimens.32 
Characteristics of the included studies 
All included studies, grouped according to the study questions are described in table 1. 
Three aspects of the risk of bias (randomization, allocation concealment, attrition bias) according 
to the Cochrane scheme were judged to be low in 13 of 16 trials, while randomization and 
allocation concealment were uncertain in two trials and considered high risk in one trial. High risk 
of bias due to lack of blinding applied to all trials with respect to SMN and PFS, OS was presumed 
to be entirely objective. Sixteen patients from two studies with no evaluable data after 
randomization were excluded from the meta-analysis.20, 26 Those patients had also been excluded 
from the analyses of the respective study groups. 
The median follow-up within the trials ranged between 3.5 and 17.6 years (overall median follow-
up: 7.4 years). A histogram of follow-up times to SMN or last information is displayed in Fig. 6 
(online only); although 75% of patients had more than 5 years of follow-up, only 16% were 
followed beyond 10 years. A comparison of the distribution of follow-up times between the 
treatment arms of the included studies yielded a significant difference according to the log-rank 
test (p=0.036) in only one of 16 cases.  
8 
 
The IQR-DLI varied among trials from 0.4 to 6.6 years (median: 3.1 years). Studies with longer 
follow-up tended to have a wider scatter. The ratio between the IQR-DLI and the median follow-up 
varied between 0.05 and 0.59 (median: 0.34). Thus, in half of the included studies the central 50% 
of last information dates stretch over a time interval of at least three years or one third of the 
median follow-up duration. 
Patient characteristics 
IPD from 9498 patients treated within 16 randomized clinical trials for newly diagnosed HL were 
included. At the time of HL treatment, patients were aged between 14 and 75 according to 
inclusion criteria of the included studies (eight exceptions between ten and 87 years), median age 
was 33 years. During the course of follow-up, an SMN was reported for 438/9498 patients (4.6%), 
including 63 t-AML/MDS (0.7%), 86 secondary NHL (0.9%) and 276 (2.9%) secondary solid 
tumors. Breast (39/276), lung (35/276), skin (29/276) and bowel (colon, rectum) (23/276) were the 
sites most often affected. In 13 patients (0.1%) diagnosed with an SMN, information on the tumor 
entity was lacking. Cumulative incidences of SMN at five, ten, 15 and 20 years (regarding death as 
a competing risk) were 2.4%, 5.8%, 13% and 23% respectively. 
Results of the treatment comparisons 
(1) CMT vs chemotherapy alone 
A total of 1011 patients treated within the EORTC 20884 (advanced stages), EORTC-GELA H9-F 
(early stages) and GHSG HD3 (advanced stages) trials were analyzed. After a median follow-up of 
7.8 years, 30/671 patients (4.5%) treated with CMT and 10/340 patients (2.9%) treated with 
chemotherapy alone had been diagnosed with an SMN. This difference was significant, favoring 
patients who had received chemotherapy only (p=0.010; Peto´s OR: 0.43, 95%-CI: 0.23-0.82) 
(figures 2, 3; table 2). Especially patients aged 50 and younger (p=0.04), female patients (p=0.01) 
and those with advanced stages (p=0.01) had a significantly reduced risk to develop an SMN 
when treated with chemotherapy alone. No reduced SMN rate with chemotherapy alone was 
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observed among patients diagnosed with early stages (p=0.68). An analysis separately evaluating 
the incidence rates for t-AML/MDS, secondary NHL and secondary solid tumors revealed a risk 
reduction after chemotherapy alone only for the development of t-AML/MDS (p=0.037) but not for 
secondary NHL and solid tumors. The PFS and OS rates did not significantly differ between 
treatment groups (table 2). However, there was some evidence of inferior tumor control with 
chemotherapy alone (HR: 1.31, 95%-CI: 0.99-1.73, p=0.06). Subgroup analyses indicated that 
stage and age were significant effect modifiers (interaction p-values were <0.0001 (stage) and 
0.02 (age)). PFS was significantly impaired after chemotherapy alone in comparison with CMT for 
early-stage patients and patients aged ≤50 (online tables 6, 8).  
(2) More extended RT vs involved field RT 
A total of 2397 early-stage patients treated within the EORTC-GELA H8-U, the GHSG HD8, the 
Italian HD94 and the Milan trials were analyzed. After a median follow-up of 10.8 years, 91/1026 
patients (8.9%) who had received RT to more extended fields and 96/1371 patients (7.0%) who 
had received IF-RT had been diagnosed with an SMN. This difference was not statistically 
significant (p=0.32; Peto´s OR: 0.86, 95%-CI: 0.64-1.16) (online figures 6, 7). When separately 
analyzing the incidence rates of t-AML/MDS, secondary NHL and secondary solid tumors, there 
were also no significant differences between the treatment groups. The same is true for the PFS 
and OS rates (table 2). Subgroup analyses according to gender and age did not identify any 
heterogeneity of the treatment effect across any subgroups. 
(3) RT at higher doses vs RT at 20 Gy 
A total of 2962 early-stage patients treated within the EORTC-GELA H9-F, GHSG HD10 and 
GHSG HD11 trials were analyzed. After a median follow-up of 7.4 years, 54/1489 patients (3.6%) 
who had RT at a dose of 30 Gy or 36 Gy and 56/1473 patients (3.8%) who had RT at a dose of 20 
Gy had developed an SMN. Thus, the rate of SMN did not differ between the treatment groups 
(p=0.87; Peto’s OR: 1.03, 95%-CI: 0.71-1.50) (online figures 8, 9). There were also no differences 
when the rates for t-AML/MDS, secondary NHL and secondary solid tumors were separately 
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considered. The clinical outcome was similar in both treatment groups, with no differences in PFS 
and OS. Additional subgroup analyses according to gender and age did not identify differences 
between any subgroups. 
(4) More vs fewer cycles of the same chemotherapy protocol  
A total of 2403 early-stage patients treated within the EORTC-GELA H8-U, EORTC-GELA H9-U 
and GHSG HD10 trials were analyzed. After a median follow-up of 7.8 years, 48/1201 patients 
(4.0%) who had been treated with more cycles and 53/1202 patients (4.4%) who had received 
fewer cycles of the same chemotherapy protocol had developed an SMN. This difference was not 
statistically significant (p=0.65; Peto´s OR: 1.10, 95%-CI: 0.74-1.62) (online figures 10, 11). The 
SMN incidences did also not differ between the patient groups when t-AML/MDS, secondary NHL 
and secondary solid tumors were separately considered. The clinical outcome after treatment with 
more or fewer cycles of the same chemotherapy was comparable, without any significant PFS and 
OS differences. Additional subgroup analyses according to gender and age did not identify 
differences between any subgroups. 
(5) Standard-dose chemotherapy (ABVD or COPP/ABVD) vs intensified chemotherapy 
A total of 2996 advanced-stage patients treated within a GITIL-IIL trial, the GISL HD2000 trial, the 
GHSG HD9 trial, the HD9601 trial from Italy and the British LY09 and ISRCTN64141244 trials 
were analyzed. The rates of RT were comparable in both treatment groups of the included studies 
with the exception of the ISRCTN64141244 and HD9601 trials, administering Stanford V as 
intensified regimen. After a median follow-up of 6.7 years, 31/1305 patients (2.8%) who had 
received standard-dose chemotherapy (ABVD, COPP/ABVD) and 60/1691 patients (3.5%) treated 
with intensified chemotherapy protocols (escalated BEACOPP, Stanford V, ChlVPP/PABIOE, 
ChlVPP/EVA, MOPP/EBV/CAD, COPP/EBV/CAD) had developed an SMN. This difference was 
not statistically significant (p=0.15; Peto´s OR: 1.37, 95%-CI: 0.89-2.10) (figures 4, 5). When 
separately considering t-AML/MDS, secondary NHL and secondary solid tumors, an increased risk 
to develop t-AML/MDS was seen for patients treated with intensified chemotherapy protocols 
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(p=0.0028) whereas the incidence rates for secondary NHL and secondary solid tumors did not 
differ between the treatment groups (table 3). Overall, tumor control was significantly better with 
intensified chemotherapy regimens as compared with standard-dose protocols (p=0.007; HR: 
0.82, 95%-CI: (0.70 – 0.95)) while there were no significant differences in OS (p=0.12; HR: 0.85, 
95%-CI: (0.70 – 1.04)). However, subgroup analyses revealed that especially patients aged ≤50 
appear to benefit from more aggressive chemotherapy approaches as the improved PFS also 
translated into a better OS in these patients (p=0.02). In contrast with patients older than 50 years, 
patients aged ≤50 also had a significantly greater SMN risk with intensified chemotherapy 
protocols than with standard-dose chemotherapy (interaction p=0.02; treatment effect in younger 
subgroup: p=0.01). Additional subgroup analyses revealed differences between the different 
intensified protocols for PFS (interaction p<0.00001) and OS (interaction p=0.006). Patients 
treated with escalated BEACOPP had superior PFS and OS rates in comparison with those 
receiving standard-dose chemotherapy. For Stanford V, PFS was worse than with standard-dose 
chemotherapy. No PFS and OS differences in comparison with standard-dose chemotherapy were 
observed for ChlVPP/PABIOE, ChlVPP/EVA, MOPP/EBV/CAD and COPP/EBV/CAD. For SMN no 
interaction in chemotherapy subgroups were found (interaction p=0.06) (online table 8). 
All main meta-analytic results are summarized in table 2. 
Sensitivity analyses agreed with the described main analyses. The results of sensitivity analyses 
concerning censoring of incomplete follow-up periods and exclusion of NMSC are summarized in 
tables 4 and 5 (online only).  
Discussion 
The present meta-analysis including 9498 patients treated within 16 randomized clinical trials for 
newly diagnosed HL between 1984 and 2007 represents one of the largest analyses of SMN, PFS 
and OS of HL patients based on randomized comparisons. The major findings were as follows: 1) 
after a median follow-up of 7.4 years, the overall SMN rate was 4.6%; 2) compared with patients 
receiving chemotherapy alone, an increased SMN rate was observed in patients receiving CMT; 3) 
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patients with early-stage HL treated with CMT had a better PFS than patients treated with 
chemotherapy alone; 4) compared with patients receiving standard-dose chemotherapy, those 
receiving intensified chemotherapy protocols more often developed t-AML/MDS; 5) compared with 
ABVD-like protocols, PFS and OS in advanced-stage patients were improved with escalated 
BEACOPP but higher rates of SMN were observed. 
The overall SMN rate of 4.6% in the present meta-analysis was lower than in previous reports. A 
meta-analysis from our group included a total of 9312 patients treated between 1962 and 2000. 
After median follow-up times ranging between four and 32 years for the considered trials, the 
overall SMN rate was 7.6%.39, 40 A British analysis including 5798 patients treated between 1963 
and 2001 reported an SMN rate of 7.9%.4 According to a Dutch study with a median follow-up of 
19.1 years, the overall SMN rate was 23% and the risk for the development of an SMN was still 
increased 30 years after HL treatment.3 Two reasons likely contribute to the higher SMN rates in 
these previous analyses: (1) a relevant proportion of the expected secondary solid tumors that are 
often diagnosed ten or more years after HL treatment has not yet occurred in the patients included 
in the present meta-analysis due to the limited median follow-up of 7.4 years; (2) the SMN rate 
observed within the present meta-analysis is probably truly lower than the rates seen in the older 
analyses, since in recent years RT fields and doses were reduced and chemotherapy protocols 
were modified with the aim of decreasing the SMN risk.  
In the present meta-analysis, patients receiving CMT for HL had a significantly increased risk to 
develop an SMN when compared with chemotherapy alone. Figure 3 shows that at 10 years after 
first-line treatment, the absolute cumulative SMN risks are approximately 3% and 10%, a risk 
difference of 7%. This result is in line with previous analyses such as the above mentioned British 
study, in which patients treated with chemotherapy alone had a significantly lower relative risk for 
the development of an SMN than patients receiving CMT.4 Subgroup analyses of the present 
analysis separately considering t-AML/MDS, secondary NHL and secondary solid tumors detected 
a significantly increased risk after CMT only for t-AML/MDS but not for secondary NHL and 
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secondary solid tumors. This finding is consistent with older reports including a study from Italy 
comprising 1659 patients treated with RT alone, CMT or chemotherapy alone. At 15 years, the t-
AML/MDS rate after CMT was significantly higher than after chemotherapy alone (p=0.05).41 
According to the present meta-analysis, patients diagnosed with early-stage HL had a better PFS 
after CMT than after chemotherapy alone. However, this finding has to be interpreted with caution 
as it derives from only one of the included trials. Nonetheless, similar data also came from the 
randomized EORTC/LYSA/FIL H10 study and the RAPID trial conducted in the UK. These studies 
evaluated the PET-guided omission of consolidating RT after chemotherapy in patients with early-
stage HL. Both studies revealed a significantly increased event rate after chemotherapy alone also 
in patients with a good response to chemotherapy resulting in a negative interim PET.42-44 
Additional data supporting the use of CMT in early-stage HL come from a previous Cochrane 
systematic review including 1245 patients from five randomized studies and an analysis 
comprising 20.600 patients registered in the U.S. National Cancer Data Base that both have not 
only demonstrated a better PFS but also an improved OS among patients treated with CMT 
compared with chemotherapy alone.45, 46 
In the present meta-analysis, an increased t-AML/MDS rate was seen in patients receiving 
intensified chemotherapy compared with patients treated with standard-dose chemotherapy. This 
finding is consistent with other reports on t-AML/MDS after HL treatment. An analysis by the 
GHSG including 11.952 patients treated within prospective studies for newly diagnosed HL 
demonstrated that patients receiving no BEACOPP or up to four cycles of escalated BEACOPP 
had significantly lower cumulative t-AML/MDS rates than patients treated with four or more cycles 
of escalated BEACOPP (0.3% vs 0.7% vs 1.7%; p<0.0001).7 
For escalated BEACOPP, the increased t-AML/MDS risk contrasts with an improved clinical 
outcome. PFS (p<0.00001) and OS (p=0.0005) rates were better than those seen with standard-
dose protocols, i.e. ABVD or COPP/ABVD. This is in line with the results of a network meta-
analysis on the effect of the initial treatment strategy on the survival of patients with advanced HL. 
14 
 
That analysis including a total of 9.993 patients revealed a survival advantage of 10% at five years 
for escalated BEACOPP in comparison with ABVD.47 
Generally, this meta-analysis provides high-quality evidence on SMN, PFS and OS among 
patients treated for HL, as the used data are from participants of large randomized trials for the 
first-line treatment of HL. However, the analysis has some limitations. With a median overall 
follow-up of 7.4 years, valid estimates are only possible for secondary hematological malignancies 
while final conclusions regarding secondary solid tumors that often occur more than ten years after 
HL cannot be drawn. Long-term data of HL patients treated within clinical trials are therefore 
necessary but often difficult to obtain due to different factors including a limited duration of 
insurance for study participants and a lack of funding sources. There is also some uncertainty 
about the completeness of SMN reporting which is of particular importance due to the small 
number of SMN events. Finally, for certain outcomes and study questions there was a 
considerable heterogeneity of up to 89% between the included trials which means that the overall 
meta-analytic results may not apply in all situations. 
Nonetheless, given the relevant proportion of HL patients that have developed an SMN already 
after a median observation of 7.4 years, the present report underscores the need for treatment 
approaches allowing a more accurate allocation to defined risk groups, in order to prevent 
overtreatment and reduce the risk for the development of potentially fatal SMN. At present, interim 
PET is considered the most promising tool to stratify treatment. Some mature results addressing 
this issue are already available and additional studies will be analyzed in the near future.48, 49 The 
replacement of conventional chemotherapy by novel agents such as the CD30-directed antibody-
drug conjugate brentuximab vedotin and antibodies targeting the programmed death cell protein 1 
(PD-1) may also reduce the risk for the development of SMN.50, 51  
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Table 1: Description of included studies 
Comparison 
(standard vs. 
experimental) 
Study Stage 
Recruitment Follow 
up Treatment arm N 
Start Length 
     (y) 
Median 
(y)  Standard Experimental Total Standard 
Experi
mental 
CMT vs 
chemotherapy 
alone 
EORTC 20884 (19) IIIA-IVB 1989 10.7 9.0 6-8MOPP/ABV + IF 6-8MOPP/ABV 333 172 161 
GHSG HD3 (24) IIIB-IVB 1984 4.2 12.9 3(COPP+ABVD) + IF 4(COPP+ABVD) 100 51 49 
EORTC-GELA H9-F 
(21) IA-IIB 1998 5.75 6.6 6EBVP+ 20/36Gy IF 6EBVP 578 448 130 
Extended vs 
involved-field RT 
(after CT) 
GHSG HD8 (25) IA-IIIA 1993 5 10.3 4COPP/ABVD + EF 4COPP/ABVD + IF 1064 532 532 
Milan (30) IA-IIA 1990 6.5 17.5 4ABVD + STNI 4ABVD + IF 140 68 72 
EORTC-GELA H8-U 
(20) IA-IIB 1993 6 8.8 4MOPP/ABV + STNI 4/6MOPP/ABV + IF 984 324 660 
HD94 Rome (31) IA-IIIA 1994 4 10.5 4ABVD + EF 4ABVD + IF 209 102 107 
Higher dose vs 20 
Gy RT 
(after CT) 
GHSG HD10 (22) IA-IIB 1998 4.75 7.5 2/4ABVD + 30Gy IF 2/4ABVD + 20Gy IF 1163 575 588 
GHSG HD11 (23) IA-IIB 1998 4.75 7.4 4ABVD/4BEACOPP  
+30Gy IF 
4ABVD/4BEACOPP  
+20Gy IF 1351 675 676 
EORTC H9-F (21) IA-IIB 1998 5.75 6.6 6EBVP+36Gy IF 6EBVP+20Gy IF 448 239 209 
More vs fewer CT 
cycles 
EORTC H8U (20) IA-IIB 1993 6 8.8 6MOPP/ABV + IF 4MOPP/ABV + IF 669 336 333 
EORTC H9-U (21) IA-IIB 1998 4 7.0 6ABVD +RT 4ABVD +RT 553 276 277 
GHSG HD10 (22) IA-IIB 1998 4.75 7.5 4ABVD + 20/30Gy IF 2ABVD + 20/30Gy IF 1190 596 594 
Standard-dose vs 
intensified CT 
(regimen +/- RT) 
GHSG HD9 (26) IIB-IVB 1993 5.2 8.6 8COPP/ABVD 8BEACOPPesc 727 261 466 
IIL HD9601 (28) IIB - IVB 1996 4.3 6.9 6ABVD Stanford V or 6MEC 335 122 213 
GISL HD2000 (27) IIB-IVB 2000 7.25 3.5 6ABVD 6BEACOPP or 6CEC 295 99 196 
GITIL-IIL NCT 
01251107 (29) IB*, IIB-IVB 2000 7.0 4.6 6-8ABVD 
4BEACOPPesc + 
4BEACOPPbas 331 168 163 
UKLG LY09 Alt (32) 
UKLG LY09 Hyb (32) 
IA-IVB 
IA-IVB 
1998 
1998 
3.7 
3.7 
7.9 
8.1 6-8ABVD 
6-8CHLVPP/EVA Hybrid 
6/8ChlVPP/PABLOE alternating 
569 
219 
287 
107 
282 
112 
UKLG 
ISRCTN64141244 
(33)  
I-IV** 1998 3.7 5.5 ABVD Stanford V 520 261 259 
*only 1 patient, ** symptoms not specified, CMT = combined-modality treatment, RT = radiotherapy, CT = chemotherapy, y=year, IF = involved field, EF = extended field, STNI = subtotal nodal 
irradiation, EORTC = European Organization for Research and Treatment of Cancer, GELA = Groupe d’Etude des Lymphomes de l’Adulte, GHSG = German Hodgkins' Study Group, GISL = 
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Gruppo Italiano per lo Studio dei Linfomi, GITIL = Gruppo Italiano di Terapie Innovative nei Linformi, IIL = Intergruppo Italiano Linformi, UKLG = United Kingdom National Cancer Research 
Institute Lymphoma Group. 
MOPP/ABV = mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine 
EBVP = epirubicin, bleomycin, vinblastine, prednisone 
ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine 
BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone 
COPP/ABVD = cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine 
CEC = COPPEBVCAD = cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, bleomycin 
MEC = MOPP/EBV/CAD = mechlorethamine, vincristine, procarbazine, prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine, doxorubicin, vindesine 
Stanford V = adriamycin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, prednisone 
ChlVPP/PABlOE = chlorambucil, vinblastine, procarbazine, prednisolone/prednisolone, doxorubicin, bleomycin, vincristine, etoposide 
ChlVPP/EVA = chlorambucil, vinblastine, procarbazine, prednisolone/etoposide, vincristine, doxorubicin
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Table 2: Treatment effect and heterogeneity for secondary malignant neoplasms (SMN), overall 
survival (OS) and progression free survival (PFS) 
Summary of main results 
Comparison 
(standard vs. 
experimental) 
SMN OS PFS 
OR 
(95%-CI) I
2
 N HR (95%-CI) I
2
 N HR (95%-CI) I
2
 N 
CMT vs 
chemotherapy 
alone 
0.433 
(0.28 – 
0.82) 
0% 
30 
(4.5%) 
vs 10 
(2.9%) 
0.71 
(0.46 - 
1.11) 
39% 
53 
(7.9%) 
vs 31 
(9.1%) 
1.31 
(0.99 – 
1.73) 
89% 
123 
(18.3%) 
vs 83 
(24.4%) 
Extended vs 
involved-field RT 
(after CT) 
0.862 
(0.64 – 
1.16) 
67% 
92 
(9.0%) 
vs 96 
(7.0%) 
0.89 
(0.70 – 
1.12) 
0% 
132 
(12.9%) 
vs 155 
(11.3%) 
0.99 
(0.81 – 
1.21) 
0% 
175 
(17.1%) 
vs 224 
(16.3%) 
Higher dose vs 
20 Gy RT 
(after CT) 
1.032 
(0.71 – 
1.50) 
72% 
54 
(3.6%) 
vs 56 
(3.8%) 
0.91 
(0.65 – 
1.28) 
0% 
72 
(4.8%) 
vs 66 
(4.5%) 
1.20 
(0.97 – 
1.48) 
1% 
165 
(11.1%) 
vs 190 
(12.9%) 
More vs fewer 
CT cycles 
1.096 
(0.74 – 
1.62) 
0% 
48 
(4.0%) 
vs 53 
(4.4%) 
0.99 
(0.73 – 
1.34) 
0% 
82 
(6.8%) vs 
82 
(6.8%) 
1.15 
(0.91 - 
1.45) 
31% 
133 
(11.0%) 
vs 152 
(12.6%) 
Standard-dose 
vs intensified CT 
(regimen +/- RT) 
1.37 
(0.89 – 
2.10) 
11% 
31 
(2.4%) 
vs 60 
(3.6%) 
0.85 
(0.70 – 
1.04) 
63% 
191 
(14.6%) 
vs 213 
(12.6%) 
0.82 
(0.70 – 
0.95) 
85% 
350 
(26.8%) 
vs 372 
(22.0%) 
CMT = combined-modality treatment, RT = radiotherapy, CT = chemotherapy, OR = odds ratio by 
Peto method, HR = hazard ratio by Cox regression, CI = confidence interval, I2 = heterogeneity, N = 
number of events 
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Table 3: Summary of SMN results for each SMN type 
Comparison 
(standard vs. 
experimental) 
Solid tumor t-AML/MDS NHL 
 
OR p OR p OR p 
CMT vs 
chemotherapy alone 
0.627 0.29 0.293 0.037 0.325 0.21 
Extended vs involved-
field RT (after CT) 
0.851 0.37 0.517 0.14 1.18 0.66 
Higher dose vs 20 Gy 
RT (after CT) 
1.20 0.43 0.662 0.65 0.845 0.67 
More vs fewer CT 
cycles 
1.15 0.56 0.261 0.10 1.94 0.13 
Standard-dose vs 
intensified CT 
(regimen +/- RT) 
1.00 1.0 4.51 0.0028 0.61 0.26 
t-AML/MDS = therapy-related acute myeloid leukemia/myelodysplastic syndromes, NHL = non- 
Hodgkin lymphomas, CMT = combined-modality treatment, RT = radiotherapy, CT = chemotherapy, 
OR = Peto odds ratio, p = p-value 
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Figures – Legend 
 
Figure 1: Search results (combined for both searches in 2010 and 2015). HL = 
Hodgkin lymphoma, IPD = individual patient data 
Figure 2: Additional Radiotherapy, secondary malignant neoplasms, forest plot for 
Peto Odds Ratios. CI = confidence interval, O-E = observed minus expected, V = 
variance, I2 = measure of heterogeneity 
Figure 3: Additional radiotherapy, cumulative incidence of SMN (Peto meta-analysis). 
Vertical bars depict approximate 95% confidence intervals (CI) for cumulative 
incidence rates. CT = chemotherapy, RT = radiotherapy. 
Figure 4: Intensified chemotherapy, secondary malignant neoplasms, forest plot for 
Peto Odds Ratios. CI = confidence interval, O-E = observed minus expected, V = 
variance, I2 = measure of heterogeneity 
Figure 5: Intensified chemotherapy, cumulative incidence of SMN (Peto meta-
analysis). Vertical bars depict approximate 95% confidence intervals (CI) for 
cumulative incidence rates 
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List of Figures with titles and legends 
Supplemental Figure 1: Histogram of the distribution of follow-up times to secondary 
malignant neoplasm 
Supplemental Figure 2: Radiotherapy field, secondary malignant neoplasms, forest 
plot for Peto Odds Ratios. IF = involved field, EF = extended field, CI = confidence 
interval, O-E = observed minus expected, V = variance, I2 = measure of 
heterogeneity 
Supplemental Figure 3: Radiotherapy field, cumulative incidence of SMN (Peto meta-
analysis). Vertical bars depict approximate 95% confidence intervals (CI) for 
cumulative incidence rates. IF = involved field, EF/STNI = extended field / subtotal 
nodal irradiation 
Supplemental Figure 4: Radiotherapy dose, secondary malignant neoplasms, forest 
plot for Peto Odds Ratios. CI = confidence interval, O-E = observed minus expected, 
V = variance, I2 = measure of heterogeneity 
Supplemental Figure 5: Radiotherapy dose, cumulative incidence of SMN (Peto 
meta-analysis). Vertical bars depict approximate 95% confidence intervals (CI) for 
cumulative incidence rates. 
Supplemental Figure 6: Chemotherapy cycles, secondary malignant neoplasms, 
forest plot for Peto Odds Ratios. CI = confidence interval, O-E = observed minus 
expected, V = variance, I2 = measure of heterogeneity 
Supplemental Figure 7: Chemotherapy cycles, cumulative incidence of SMN (Peto 
meta-analysis). Vertical bars depict approximate 95% confidence intervals (CI) for 
cumulative incidence rates. 
 







